Welcome to our dedicated page for Sonoma Pharmaceu news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceu stock.
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) is frequently in the news for developments related to its stabilized hypochlorous acid (HOCl) products based on patented Microcyn technology. The company issues regular updates on product launches, regulatory milestones, distribution partnerships, and financial results, giving investors and industry observers insight into how its HOCl portfolio is being deployed in wound care, eye care, oral and nasal care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants.
News coverage often highlights Sonoma’s expansion into consumer and professional markets. Recent press releases describe HOCl-based diaper rash products for infants and children launched into large U.S. retailers, hypochlorous acid-based acne products placed in retail pharmacy chains in the United Kingdom, and a Microcyn-based facial spray listed under the FDA’s Modernization of Cosmetics Regulation Act of 2022 (MoCRA). The company also reports on collaborations such as its HOCl wound cleanser manufactured for Medline Industries, LP for distribution into U.S. hospital systems and home healthcare channels.
Regulatory and recognition updates are another key theme. Sonoma has announced successful transition of its European products to the EU Medical Device Regulation (MDR), registrations with the MHRA in the United Kingdom, and multiple seals for Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel from organizations such as the National Psoriasis Foundation and the National Rosacea Society. Financial news includes quarterly and annual results, revenue trends by region, and non-GAAP metrics such as EBITDA loss.
By following the SNOA news feed, readers can monitor how Sonoma’s HOCl-based products are progressing through new markets, how its regulatory footprint is evolving, and how these developments are reflected in reported financial performance and corporate actions.
Sonoma Pharmaceuticals (NASDAQ:SNOA) celebrates its 20th anniversary of selling wound care products in Europe. The company, known for its patented Microcyn® technology, announced a new partnership with Smart Healthcare Company (SHC) s.r.o. to distribute its Microdacyn60® wound care products in Ukraine. SHC, based in Slovakia, will collaborate with DANA MC, a major medical supplier in Ukraine. The Microdacyn60 solution and hydrogel, based on hypochlorous acid, aid in pain relief, irritation reduction, and wound healing by eliminating bacteria, fungi, and viruses without damaging healthy tissue. CEO Amy Trombly expressed pride in the milestone and the opportunity to address significant healthcare needs in Ukraine.
Sonoma Pharmaceuticals (Nasdaq: SNOA) reported a 14% increase in Q4 2024 revenues to $3.4 million, driven by rising product sales across all territories except 'Rest of the World'. Gross profit margin improved by 3% year-over-year to 32%. Despite a 24% rise in operating expenses due to increased R&D, net loss decreased by 18% to $1.1 million. For FY 2024, revenues dropped 4.5% to $12.7 million due to lower service revenue but gross profit margin increased to 37%. Net loss for the year improved by 6% to $4.8 million. CEO Amy Trombly highlighted product innovation and market expansion as key growth drivers.
Sonoma Pharmaceuticals, Inc. announced the availability of its MicrocynAH animal health care products in Menards home improvement stores. The products include a range of items for wound care, eye and ear care, and itch relief for various animals. The expansion aims to provide pet owners with safe and effective solutions for their pets' health needs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.